

ARTICLE OPEN



Scanning ultrasound-mediated memory and functional improvements do not require amyloid- β reduction

Gerhard Leinenga¹, Xuan Vinh To^{2,3}, Liviu-Gabriel Bodea¹, Jumana Yousef^{4,5}, Gina Richter-Stretton¹, Tishila Palliyaguru¹, Antony Chicoteau¹, Laura Dagley^{4,5}, Fatima Nasrallah^{2,3} and Jürgen Götz¹✉

© The Author(s) 2024

A prevalent view in treating age-dependent disorders including Alzheimer's disease (AD) is that the underlying amyloid plaque pathology must be targeted for cognitive improvements. In contrast, we report here that repeated scanning ultrasound (SUS) treatment at 1 MHz frequency can ameliorate memory deficits in the APP23 mouse model of AD without reducing amyloid- β (A β) burden. Different from previous studies that had shown A β clearance as a consequence of blood-brain barrier (BBB) opening, here, the BBB was not opened as no microbubbles were used. Quantitative SWATH proteomics and functional magnetic resonance imaging revealed that ultrasound induced long-lasting functional changes that correlate with the improvement in memory. Intriguingly, the treatment was more effective at a higher frequency (1 MHz) than at a frequency within the range currently explored in clinical trials in AD patients (286 kHz). Together, our data suggest frequency-dependent bio-effects of ultrasound and a dissociation of cognitive improvement and A β clearance, with important implications for the design of trials for AD therapies.

Molecular Psychiatry; <https://doi.org/10.1038/s41380-024-02509-5>

INTRODUCTION

Alzheimer's disease (AD) is the leading cause of disability in the aging population, accounting for up to 80% of all cases of dementia. The overarching histopathological feature is that two key molecules, amyloid- β (A β) and tau, form insoluble aggregates. These develop into microscopically visible brain lesions known as A β plaques and neurofibrillary tangles that contain tau [1]. Both A β and tau dysfunction are believed to initiate and drive the degenerative process in AD, leading to a progressive impairment of memory, reasoning, and social engagement [2]. A routinely used system to model aspects of AD and other dementias is represented by transgenic mice [3]. A β plaque formation, together with memory impairment, has been reproduced in several transgenic lines including APP23 mice. This strain expresses the human amyloid precursor protein (APP) together with the K670N/M671L pathogenic mutation present in familial cases of AD [4].

Given the challenges of developing effective pharmacological treatments for AD and other brain diseases, alternative strategies including low-intensity focused ultrasound (FUS) are currently being explored [5]. At high intensity, ultrasound is being used as a focused, incisionless, FDA-approved surgical tool for ablating brain tissue and thereby treating diseases such as essential tremor and tremor-dominant Parkinson's disease [6]. At low intensity, ultrasound is being investigated as neuromodulatory and/or blood-brain barrier (BBB) opening tool in multiple animal species and human study participants [5, 6].

To achieve its bio-effects, ultrasound induces mechanical effects, which can be categorized into acoustic radiation forces


and cavitation. Thermal effects are largely negligible at low ultrasound intensities. When ultrasound is delivered focally and interacts with intravenously injected microbubbles (FUS^{+MB}), cavitation is augmented, leading to BBB opening. This causes an uptake of blood-borne factors, some of which with therapeutic effects [6]. FUS^{+MB} is used by us in a scanning mode, SUS^{+MB}, to treat the entire brain. Several research groups have thereby been able (i) to reduce amyloid plaque load in AD mouse models (such as the APP23 mice), without co-injecting exogenous drugs [7–9], and (ii) to improve memory functions [7–9]. Following treatment, A β was found to be taken up and cleared by microglial cells. This robust A β clearance was assumed to be the reason for the improved memory functions.

Ultrasound has also been explored without delivering microbubbles (termed by us FUS^{only} or SUS^{only}), a modality whereby cavitation effects are largely absent and the effects of ultrasound are neuromodulatory, utilizing mechanical forces. Such a SUS^{only} treatment, however, proved insufficient to clear A β [10]. Given that low-intensity ultrasound is increasingly being explored as a novel treatment option in AD patients, either with microbubbles [11–13] or without microbubbles [14], we asked whether the SUS^{only} treatment paradigm could improve spatial memory in APP23 mice, and whether A β reductions are required as one may assume because A β is the culprit causing the cognitive impairments in the first place. Here, we explored two frequencies: We used 1 MHz (in the following, we term this SUS^{only} paradigm HighF), a frequency routinely used in mice for the purpose of BBB opening [8, 15] and via intracranially

¹Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia. ²Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia. ³Centre for Advanced Imaging, The University of Queensland, Brisbane, QLD, Australia. ⁴Proteomics Facility, Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. ⁵Department of Medical Biology, The University of Melbourne, Parkville, VIC 3052, Australia. ✉email: j.goetz@uq.edu.au

Received: 7 August 2023 Revised: 27 February 2024 Accepted: 29 February 2024

Published online: 18 March 2024



implanted transducers in AD patients [13]. We also used 286 kHz (terming this SUS^{only} paradigm LowF), this being a frequency that is within the range (210–650 kHz) at which transcranial human FUS^{+MB} treatments are generally being performed [11, 12], because at 1 MHz, attenuation and aberration of the

human skull are too high to achieve safe and efficacious bio-effects.

Interestingly, we found that repeated HighF treatments of APP23 mice, unlike LowF treatments, improved spatial memory in the active place avoidance (APA) behavior-testing paradigm.

Fig. 1 Study design and spatial memory improvements in APP23 mice in response to SUS^{only} at 1 MHz (HighF). **A** APP23 mice aged 11 months were treated with scanning ultrasound (SUS^{only}) at 1 MHz center frequency (HighF) or 286 kHz center frequency (LowF) with conditions arriving at the same pressure inside the skull, accounting for the higher attenuation of high frequency ultrasound. Exposure of the whole brain was achieved by treating a 5 × 6 grid of spots with the HighF device, and 4 spots with the LowF device, taking into account the different -6 dB widths of the ultrasound focus at HighF (1 MHz, 1.5 mm) versus LowF (286 kHz, 6 mm). **B** APP23 mice and wild-type (WT) littermate controls were tested in the active place avoidance (APA) test over 5 days of training. APP23 mice then received eight once-per-week ultrasound treatments with either the HighF or LowF device. Controls received a sham treatment consisting of anesthesia and being placed under the ultrasound transducer, but the transducer was not turned on. WT mice were sham treated. Three days after the last ultrasound treatment, mice were retested in the APA (retest) in which the extra-maze cues were changed, the shock zone was placed in the opposite quadrant, and the arena rotated in a different direction. Between 2 and 7 days after the conclusion of the APA, mice received magnetic resonance imaging (MRI) scans and were sacrificed at the conclusion of the scans. **C** Schematic of the arena for the APA test, in which mice must use spatial cues to learn to avoid a shock zone within a rotating arena. APP23 mice show impaired performance compared to their WT littermates on the measures **(D)** number of shocks, **(E)** time to first entry of the shock zone, and **(F)** time to second entry to the shock zone. (Two-way ANOVA, **p* < 0.05, APP23 compared to WT). **G** All mice were ranked based on their performance on the last day (day 5) of the APA and allocated to groups based on matching performance. **H** Following eight ultrasound treatments (1 MHz ultrasound (HighF), 286 kHz ultrasound (LowF) or sham), the mice were retested in the APA with the shock zone location, extra-maze cues and the direction of the arena rotation altered. There were significant differences between the treatment groups, such that compared to sham treated APP23 mice, **(I)** HighF-ultrasound treated APP23 mice and sham treated WT mice received fewer shocks, **(J)** had an increased time to first entry on day five **(K)**, and had an increased time to second entry of the shock zone. **L** HighF treated APP23 mice received significantly fewer shocks on day five of the APA retest compared to sham treated APP23 mice. (Two-way ANOVA with follow-up Holm–Sidak test, #*p* < 0.05 HighF compared to sham, **p* < 0.05 WT compared to sham treated APP23 mice, #*p* < 0.05 HighF treated APP23 mice compared to sham treated APP23 mice). **M** A learning index was calculated by dividing the number of shocks received on day five compared to day one of the APA retest, with better learning indicated by a lower ratio on the learning index measure. HighF mice demonstrated better learning on this index (One-way ANOVA with Holm–Sidak multiple comparisons test, **p* < 0.05).

Contrary to the prevalent view that A β pathology (in addition to tau) drives the degenerative process and that for cognitive functions to improve, A β needs to be reduced, we found that the memory improvements occurred in the absence of A β reductions. Reduced neuronal connectivity may be responsible for the symptoms of AD. Resting-state functional magnetic resonance imaging (rsfMRI) connectivity studies in AD patients have shown that there is a dysfunction in network-level organization of the brain, including the default mode, salience, and limbic networks [16, 17]. We therefore also investigated whether ultrasound treatment achieves a long-lasting modulation of these dysfunctional brain networks and therefore represents an alternative therapeutic approach to AD. Our results revealed that SUS^{only}, particularly at the 1 MHz frequency, induced long-term structural and functional changes in neurons and their connections, as revealed by quantitative proteomics and analysis of correlations between rsfMRI and behavior testing. Together, our data suggest a dissociation of cognitive improvement and A β clearance, with important implications for AD treatment strategies. They further suggest that the current clinical trials may not use optimal ultrasound parameters, with our data providing new insights for ultrasound treatment optimization.

MATERIALS AND METHODS

Study design

APP23 mice express human APP751 with the Swedish double mutation (KM670/671NL) under the control of the neuron-specific mThy1.2 promoter. As the mice age, they exhibit memory deficits and amyloid plaque formation [18]. In this study, 11 month-old APP23 mice were assigned to three treatment groups: sham (*N* = 12), 1 MHz ultrasound (*N* = 12, HighF), and 286 kHz ultrasound (*N* = 11, LowF). Assignment to treatment groups was based on matching performance of spatial memory (number of shocks) on day 5 of the APA test. APP23 mice were ranked from those receiving the fewest shocks to those receiving the most shocks on day 5 and were assigned to the three APP23 ultrasound treatment groups in rank order. A group of wild-type mice (*N* = 12) was included as fourth group. Following eight weekly treatments, mice underwent an APA re-test over five days, followed by an MRI analysis and the collection of brains for a proteomic, biochemical and histological analysis (Fig. 1).

Animal ethics

All animal experimentation was approved by the Animal Ethics Committee of the University of Queensland (approval number QBI/554/17).

Ultrasound equipment

For the 286 kHz ultrasound application, a H-117 transducer was used (Sonic Concepts Bothell WA USA). This transducer has a diameter of 64 mm, a radius of curvature of 63 mm, and an internal opening diameter of 20 mm. For the 1 MHz ultrasound application, an integrated focused ultrasound system was used (Therapy Imaging Probe System, TIPS, Philips Research). This system consists of an annular array transducer with a natural focus of 80 mm, a radius of curvature of 80 mm, a spherical shell of 80 mm with a central opening diameter of 31 mm, a 3D positioning system, and a programmable motorized system to move the ultrasound focus in the x and y planes to cover the entire brain area. A coupler mounted to the transducer was filled with degassed water and placed on the depilated head of the mouse with ultrasound gel for coupling, to ensure propagation of the ultrasound to the brain.

Ultrasound application

Mice were anesthetized with ketamine (90 mg/kg) and xylazine (6 mg/kg), and the hair on the head was shaved and depilated. The parameters for ultrasound delivery for the LowF condition were: 286 kHz center frequency, 0.57 MPa peak rarefactional pressure in situ (as estimated by needle hydrophone measurements obtained in water and assuming negligible attenuation through the skull), 10 Hz pulse repetition frequency (PRF), 10 ms pulse length (PL), and a 6 s sonication time per spot. Ultrasound was generated by a H-117 model transducer (Sonic Concepts) with a 64 mm diameter, a 63.2 mm radius of curvature and a 22 mm inner opening. The -6 dB focal zone was 6 mm (lateral) × 39.5 mm (axial). A motorized positioning system moved the focus of the transducer array to four spots spaced 6 mm apart in relation to the skull such that the entire brain of the mouse was exposed to ultrasound. The HighF condition was: 1 MHz center frequency, 0.7 MPa peak rarefactional pressure (as estimated by needle hydrophone measurements in water for device calibration), 10 Hz PRF, 10 ms PL, and 6 s sonication per spot (Fig. 1). Ultrasound was generated by an eight-element annular array (TIPS system, Philips Research) with a diameter of 80 mm with an inner hole of 32 mm and an 80 mm radius of curvature. The focal zone of the array (-6 dB) was an ellipse of approximately 1.5 mm × 1.5 mm × 12 mm. The TIPS motorized positioning system moved the focus of the transducer array in a grid with 1.5 mm between individual sites of sonication such that ultrasound was delivered sequentially to the entire brain. The pressure level inside the brain was adjusted to be equivalent for the HighF and LowF ultrasound groups (0.57 MPa derated pressure), accounting for the higher, estimated 18% attenuation of 1 MHz ultrasound by the mouse skull [19].

Assessment of amyloid plaques

For the assessment of amyloid plaque load, an entire one-in-eight series of coronal brain sections taken from the start of the anterior commissure to

the ventral hippocampus of one hemisphere at 40 μm thickness was stained using the Campbell-Switzer silver staining protocol that stains both compact plaques and more diffuse amyloid fibrils, although we did not distinguish these types in our analysis [8]. Stained sections were mounted onto microscope slides and imaged with a 10x objective on a Metafer bright-field VSlide scanner (MetaSystems) using Zeiss Axio Imager Z2. Analysis of amyloid plaque load was performed using FIJI on all stained sections using ImageJ. A region of interest (ROI) was drawn around the cortex, and automated thresholding for plaques was applied to the ROIs, with the 'fill holes' and 'despeckle' functions applied to allow all plaques to be counted. A size threshold of 50 μm^2 was applied to determine the number of plaques per area. No size thresholding was applied for the calculation of total plaque burden.

Enzyme-linked immunosorbent assay for A β

Frozen cortices were homogenized in 10 volumes of a solution containing 1% sodium deoxycholate in 0.1 M phosphate buffered saline with Complete™ protease inhibitors (Roche), and homogenized by passing through 19 and 27 gauge needles. The samples were then centrifuged at 21,000 $\times g$ for 90 min at 4°C. The supernatant was retained as the detergent-extracted soluble A β fraction. The remaining pellets were resuspended in 10 volumes of 5 M guanidine HCl, sonicated, and centrifuged at 21,000 $\times g$ for 30 min at 4°C. The resultant supernatant was retained as the guanidine-extracted insoluble A β fraction. The concentrations of A β_{40} and A β_{42} were determined in brain lysates using ELISA kits according to the manufacturer's instructions (human A β_{40} and A β_{42} brain ELISA, Invitrogen).

Isolation of synaptic proteins from hippocampi

Subcellular fractionation was performed on hippocampi as previously described [20]. Hippocampi that were frozen in sucrose buffer were thawed and homogenized on ice in sucrose buffer (0.32 M sucrose, 10 mM HEPES, pH 7.4). An aliquot of the homogenate was sonicated and used as the 'hom' fraction. The remainder was centrifuged at 1000 $\times g$ for 10 min at 4°C, yielding a supernatant fraction (S1) and a nuclear enriched pellet (P1). The P1 pellet was resuspended in RIPA buffer, followed by sonication to produce a nuclear fraction (N). The supernatant (S1) was centrifuged at 14,000 $\times g$ for 20 min at 4°C to obtain a crude synaptosomal fraction (P2) and a cytosolic protein (Cyto) enriched supernatant (S2). The P2 pellet was washed twice with wash buffer (4 mM HEPES, 1 mM EDTA, pH 7.4) followed by resuspension and centrifugation at 12,000 $\times g$ for 20 min at 4°C. It was then resuspended in buffer A (20 mM HEPES, 100 mM NaCl, 0.5% Triton X-100, pH 7.2). After rotation at 4°C for 1 h, the suspension was centrifuged at 12,000 $\times g$ for 20 min at 4°C to yield the supernatant S3 non-PSD fraction containing extrasynaptic proteins. The resulting pellet (P3) was washed twice in wash buffer and resuspended in buffer B (20 mM HEPES, 0.15 mM NaCl, 1% Triton X-100, 1% SDS, 1 mM dithiothreitol, 1% deoxycholate, pH 7.5) for 1 h at 4°C, followed by centrifugation at 10,000 $\times g$ for 20 min at 4°C to obtain the supernatant S4 postsynaptic density (PSD) fraction containing synaptic proteins (PSD), on which a BCA assay was run (Thermo-Fisher). All buffers were freshly supplemented with a protease and phosphatase inhibitor cocktail (Merck/Sigma) prior to use, and fractions were stored as aliquots at -80°C.

Western blotting

Equal amounts of protein were loaded (20 μg for detection of synaptic tau in the hippocampal PSD fraction and 40 μg for detection of tau in the cortical homogenate) and resolved by SDS-PAGE (4–15% Criterion TGX Precast Gels from Bio-Rad) in Tris-glycine-SDS buffer (Bio-Rad), followed by transfer onto low fluorescence polyvinylidene fluoride membranes (Bio-Rad) as previously described [20]. After transfer, the membranes were incubated with REVERT total protein stain (LI-COR) for 5 min and washed in wash buffer (6.7% v/v glacial acetic acid, 30% v/v methanol in water), and then scanned with the 700 nm channel in the Odyssey Fc Imaging system (LI-COR) for loading control analysis. The membranes were incubated in REVERT reversal solution (0.1 M sodium hydroxide, 30% v/v methanol in water) for 5 min. They were then blocked with Odyssey blocking buffer (LI-COR) for 1 h, and reacted with primary antibodies in Odyssey blocking buffer (LI-COR) in Tris-buffered saline containing 0.05% Tween-20 (TBS-T) overnight at 4°C under gentle rocking. Primary antibodies were tau-5 (Millipore, Cat#MAB361 1:1,000 dilution), phospho-tau 404 (Thermo-Fisher, Cat#44-758 G, 1:1,000 dilution) and PSD95 (Cell Signaling, Cat#3450, 1:1,000 dilution). After washing in TBS-T, secondary antibodies conjugated

with IR 680RD/800CW (LI-COR 1:10,000) were added for 1 h at room temperature under gentle rocking. After washing in TBS-T, the membranes were scanned in the Odyssey Fc Imaging system (LI-COR) for detection of an infrared signal, and the signal was normalized to REVERT total protein stain according to the manufacturer's protocol.

Active place avoidance test

The APA task is a test of hippocampus-dependent spatial learning. We used a repeated APA paradigm, where mice were tested in the APA once and the performance of each mouse was used to assign that mouse to one of four treatment groups. This was done by ranking all the mice based on their performance and assigning them to the four groups to ensure that the APA performance of each treatment group was the same. Following this, mice received either sham, HighF or LowF treatment. Three days after the last treatment, they were retested to assess whether there was an improvement in APA performance. For each APA test, APP23 mice and non-transgenic littermate controls were tested over 6 days in a rotating elevated arena (Bio-Signal group) that had a grid floor and a 32-cm-high clear plastic circular fence enclosing a total diameter of 77 cm. High-contrast visual cues were present on the walls of the testing room. The arena and floor were rotated at a speed of 0.75 rpm, with a mild shock (500 ms, 60 Hz, 0.5 mA) being delivered through the grid floor each time the animal entered a 60-degree shock zone, and then every 1500 ms until it left the shock zone. The shock zone was maintained at a constant position in relation to the room. Recorded tracks were analyzed with Track Analysis software (Bio-Signal). A habituation session was performed 24 h before the first training session during which the animals were allowed to explore the rotating arena for 5 min without receiving any shocks. A total of five training sessions were held on consecutive days, one per day with a duration of 10 min. After day 5 of the first APA 'test', APP23 mice were divided into three groups to receive treatment (HighF, LowF, sham) with mice matched so that the performance (number of shocks) of the four groups of mice on day 5 of the task was the same for the 'retest'. Following eight once-a-week sham or ultrasound treatments, the mice underwent the APA test again (reversal learning). The retest was held in the same room as the initial test. However, the shock zone was switched to the opposite side of the arena, the visual cues were replaced with different ones, and the platform was rotated clockwise rather than counter-clockwise. The number of shocks, numbers of entries to the shock zone, time to first entry, time to second entry, and proportion of time spent in the opposite quadrant to the shock zone were compared over the days of testing.

Magnetic resonance imaging

Mice were imaged on a 9.4 T (Bruker Biospin) MRI scanner between 8 and 12 days after the final (8th) HighF, LowF or sham treatment. Deep anesthesia was induced with 3% isoflurane in a 60/40 mixture of air/O₂ at 1 l/min, and the isoflurane concentration was reduced to 1.5–2% for the remaining animal preparation time. Anesthetized mice were placed on an MRI-compatible cradle in a head-first, prone position and the head was fixed using ear bars and a bite bar to avoid movement. An intraperitoneal (i.p.) catheter was inserted and fixed temporarily for the infusion of medetomidine (Domitor, Pfizer) [21]. A 30-gauge tail vein catheter was inserted into one of the lateral tail veins for infusion of contrast agent (Magnevist, 0.5 mmol/kg). Subdermal electrodes were inserted near the 2nd and 4th digits on the left forepaw for mild electrical stimulations, which were delivered by a current source (Isostim A320, World Precision Instrument). The animals were monitored for respiration rate, pattern and stability, and rectal temperature (targeting 37 \pm 0.5°C) using an MRI-compatible rodent physiological monitoring system (Model 1030, SA Instruments).

Following proper positioning of the mouse inside the scanner magnet, an i.p. bolus dose of 0.05 mg/kg medetomidine was given and continuous sedation was maintained with continuous medetomidine i.p. infusion at 0.1 mg/kg/h. The isoflurane concentration was lowered gradually and maintained at 0.5% throughout the remainder of the experiment. T2-weighted, diffusion, BOLD and contrast-enhanced scans were obtained. The total time under anesthesia was approximately 2.5 h. At the end of the scan, an i.p. bolus dose of 1.25 mg/kg atipemazole (for medetomidine reversal) was given and the animals were kept on a heated pad and monitored for recovery.

The sequence parameter details for the T2-weighted (T2w) structural, stimulus-evoked and resting-state functional, and multi-shell diffusion scans have been described previously [22]. Briefly, T2w structural MRI scans

were taken with a Turbo Rapid Acquisition with Refocused Echoes (TurboRARE) sequence with TR/TE = 7200/39 ms and a resolution of $0.1 \times 0.1 \times 0.3$ mm. Stimulus-evoked and resting-state functional MRI scans were acquired with a 2D gradient-echo echo-planar-imaging (GE-EPI) sequence with TR/TE = 1000/14 ms, flip angle = 70° , and spatial resolution of $0.3 \times 0.3 \times 0.6$ mm.

A Dynamic Susceptibility Contrast (DSC) sequence was acquired using a 2D gradient-echo echo-planar-imaging (GE-EPI) sequence with the following parameters: matrix size = 64×64 , FOV = 19.2×19.2 mm, 17 slices of 0.7 mm thickness and 0.1 mm slice gaps; giving an output spatial resolution of $0.3 \times 0.3 \times 0.8$ mm, TR/TE = 550/14 ms, flip angle = 35° , bandwidth = 3125 Hz/pixel, fat suppression = ON, FOV saturation (covering the head tissue inferior to the mouse's brain) = ON, and navigator pulses = ON. The DSC sequence was started and allowed to run for 60 s before the contrast agent bolus was delivered; the DSC sequence was scanned with 982 volumes.

Magnetic resonance imaging analysis

The preprocessing and image registration of the structural, diffusion, and functional MRI images were done based on detailed procedures as previously described [23]. Briefly, structural images were corrected for bias field inhomogeneity and then normalized to a common space by an iterative image registration-template creation procedure, and the Jacobian images were used for a tensor-based morphometry analysis of structural differences. Diffusion MRI data were distortion and motion corrected, and fitted for the NODDI model, and also spatially normalized using a similar procedure as for the structural images. Orientation dispersion index (ODI), neurite density index (NDI), and fraction of isotropic diffusion (fISO) were obtained from the multi-shell diffusion MRI data. Functional MRI data were distortion and motion corrected, high-pass filtered at 0.01 Hz, and also spatially normalized before being analyzed through a data-driven group independent component analysis (group ICA) using independent vector analysis – Gaussian and Laplacian source vecos (IVA-GL) into 65 independent components. Independent components were selected and grouped into larger networks [22]. DSC MRI data were processed and spatially normalized to a common space using a process similar to that used for functional MRI data. Dynamic Susceptibility Contrast (DSC) data were fitted using the Dynamic Susceptibility Contrast MRI toolbox (<https://github.com/marcocastellaro/dsc-mri-toolbox>) with semi-automatic arterial input function selection and blood-brain barrier leakage correction [24].

SWATH mass spectrometry

To identify changes in protein abundance following HighF or LowF treatments compared to sham, total cortical protein extracts from 10–12 mice per group were analyzed by sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS). Briefly, 45 μ g of protein from each sample was diluted in triethylammonium bicarbonate buffer and subsequently reduced with DTT, followed by alkylation with iodoacetamide. Samples were then digested with 80 ng of trypsin overnight, after which they underwent a buffer exchange to be resuspended in 2% acetonitrile, 0.1% formic acid. To form a unique peptide library, 5 μ g from each of the samples were first pooled together and then fractionated via high pH reversed-phase high-performance liquid chromatography (HpH-RP-HPLC). The pooled sample was vacuum dried, resuspended in mobile phase buffer A (5 mM ammonium hydroxide solution, pH 10.5), loaded and washed with 3% buffer B (5 mM ammonia solution supplemented with 90% acetonitrile, pH 10.5) for 10 min at a flow rate of 300 μ L/min, then the buffer B concentration was increased from 3 to 30% over 55 min, and then to 70% between 55–65 min, and to 90% between 65–70 min. The eluent was collected every 2 min at the beginning of the gradient and at 1 min intervals for the rest of the gradient. The 17 fractions obtained were then analyzed via information-dependent acquisition (IDA). Following HpH-RP-HPLC separation, the fractions were concatenated (0–85 min), dried and resuspended in 60 μ L of loading buffer, and 10 μ L from each fraction was then injected onto the column for 2D-IDA analysis.

For IDA, the sample (10 μ L) was injected onto a reverse-phase peptide trap for pre-concentration and desalted with loading buffer at 5 μ L/min for 3 min. The peptide trap was then switched into line with the analytical column. Peptides were eluted from the column using a linear solvent gradient from mobile phase A: mobile phase B (95:5) to mobile phase A: mobile phase B (65:35) at 300 nL/min over a 60 min period. After peptide elution, the column was cleaned with 95% buffer B for 6 min and then equilibrated with 95% buffer A for 10 min before the next sample injection.

The reverse phase nanoLC eluent was subjected to positive ion nano-flow electrospray analysis in an IDA mode. A TOF-MS survey scan was acquired (m/z 350–1500, 0.25 s) with the 20 most intense multiply charged ions ($2^+ - 5^+$; exceeding 200 counts per s) in the survey scan sequentially subjected to MS/MS analysis. MS/MS spectra were accumulated for 100 ms in the mass range m/z 100–1800 with rolling collision energy.

For SWATH, the samples (10 μ L, ~ 2 μ g) were injected into a reverse-phase peptide trap for pre-concentration and desalted with loading buffer at 5 μ L/min for 3 min. The peptide trap was then switched into line with the analytical column. Peptides were eluted from the column using a linear solvent gradient from mobile phase A: mobile phase B (95:5) to mobile phase A: mobile phase B (65:35) at 300 nL/min over a 60 min period. After sample loading and washing with 3% buffer B for 10 min at a flow rate of 300 μ L/min, the buffer B concentration was increased from 3 to 30% over 55 min, and then to 70% between 55 and 65 min, and to 90% between 65 and 70 min. Peptides were eluted from the column using a linear solvent gradient from mobile phase A: mobile phase B (95:5) to mobile phase A: mobile phase B (65:35) at 300 nL/min over a 60 min period. After peptide elution, the column was cleaned with 95% buffer B for 6 min and then equilibrated with 95% buffer A for 10 min before the next sample injection. The reverse phase nanoLC eluent was subjected to positive ion nano-flow electrospray analysis in SWATH mode. First, a TOFMS survey scan was acquired (m/z 350–1500, 50 ms) and then, the 100 predefined m/z ranges were sequentially subjected to MS/MS analysis. MS/MS spectra were accumulated for 30 ms in the mass range m/z 350–1500.

Database searches for IDA data were performed as follows: The data files generated by IDA-MS analysis were searched with ProteinPilot (v5.0) (Sciex) using the Paragon™ algorithm in thorough mode. *Mus musculus* 'uniprot-mus_musculus' containing 17,119 proteins on July 4th 2022, was used for searching the data. Carbamidomethylation of Cys residues was selected as a fixed modification. An Unused Score cut-off was set to 1.3 (95% confidence for identification), and global protein false discovery rate (FDR) to 1%.

For SWATH extraction and quantitation, the local ion library was constructed using the 2D-IDA data. The library contained 4448 proteins. The ion library and SWATH data files were imported into PeakView (v2.2) (Sciex). Protein peak area information in SWATH data were extracted using PeakView (v2.2) with the following parameters: Top 6 most intense fragments of each peptide were extracted from the SWATH data sets (75 ppm mass tolerance and 10 min retention time window). Shared and modified peptides were excluded. After data processing, peptides (max 100 peptides per protein) with confidence $\geq 99\%$ and FDR $\leq 1\%$ (based on chromatographic feature after fragment extraction) were used for quantitation.

Bioinformatics analysis of SWATH-MS data

Data processing and analysis were performed using R (version 4.2.1). Proteins that were identified by two or more peptides were used in the analysis pipeline. A total of 2115 proteins were included in the analysis. Protein intensities were \log_2 -transformed. Normalization based on groups was performed using RUVIIIIC (v. 1.0.19). Invariant proteins in all conditions ($p > 0.5$), with a coefficient of variation (CV%) $< 2\%$, were chosen as negative controls for RUVIIIIC normalization. Differential analysis was performed using limma (v. 3.52.4). A protein was determined to be significantly differentially expressed if the fold change was ≥ 1.5 or ≤ 0.5 and the FDR was $\leq 5\%$ after Benjamini–Hochberg (H-B) correction.

Clustering analysis was performed based on mixed-effects models with Gaussian variables and a non-parametric cubic splines estimation approach implemented in TMixClust R package (v.1.18.0). GO (gene ontology) analysis and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways analysis were performed using clusterProfiler R-package (v. 4.4.4).

Statistical analysis

Statistical analyses were conducted with Prism 9 software (GraphPad). Values were always reported as mean \pm SEM. One-way ANOVA followed by the Holm–Sidak multiple comparisons test, or t test was used for all comparisons except APA analyses where two-way ANOVA with day as a repeated measures factor and group as a between-subjects factor was performed, followed by the Holm–Sidak multiple comparisons test for simple effects to compare group performances on different days. The model assumption of equal variances was tested by Brown–Forsyth or Bartlett tests, and the assumption of normality was tested by Kolmogorov–Smirnov tests and by inspecting residuals with QQ plots. All

observations were independent, with allocation to groups based on APA where mice were ranked on performance and assigned to one of the three groups (HighF, LowF and sham) in the order of number of shocks on day 5 ranked from most to least shocks.

Spatially normalized MRI outputs, including the Jacobian Index (obtained from T2w structural MRI image registration procedure), NODDI metrics (ODI, NDI, and fISO) and group ICA independent components' spatial maps were analyzed as 2 sample t-tests using permutation inference for the General Linear model as implemented in FSL's 'randomize' function [25]. The number of permutations was set to 10,000, as recommended by a prior study [26]. The resulting statistical maps were corrected for multiple comparisons with mass-based FSL's Threshold-free Cluster enhancement (TFCE) [27] and thresholded at $p < 0.05$ (two-tailed). One and two-samples statistical tests were conducted on individual level independent components' time courses using GIFT's Mancovan toolbox for IC-IC functional network connectivity (FNC) and corrected for multiple comparisons with FDR at q -value < 0.05 for one-sample t-tests and q -value < 0.1 for two-sample t-tests.

RESULTS

High-frequency SUS improves spatial memory performance

To investigate the effects of low-intensity ultrasound in the absence of microbubbles (i.e., with no opening of the BBB, SUS^{only}) in an animal model of AD, we used two types of transducers, one operating at 1 MHz and the other at 286 kHz, both achieving a similar, derated pressure of 0.57 MPa inside the skull (Fig. 1A). The study comprised four treatment arms: untreated wild-type (WT) mice, and APP23 mice that either received 8 weekly treatments at 1 MHz in a SUS^{only} scanning mode (HighF), or 286 kHz in a SUS^{only} scanning mode (LowF), or sham (i.e. with the mice being anesthetized and placed under the transducer but without receiving an ultrasound treatment) (Fig. 1B). Prior to the first treatment, the mice underwent a 5-day spatial memory and learning assessment in the APA test, followed by an allocation to the treatment arms based on their performance. Following treatment, the mice were retested using the 5-day APA spatial memory testing paradigm, and then underwent an fMRI assessment, after which they were sacrificed and the brains dissected for analysis, including label-free quantitative proteomics (Fig. 1B).

More specifically, we first examined 11 month-old APP23 mice and their wild-type littermates in the APA test, a hippocampus-dependent spatial learning paradigm in which the animals must use visual cues to learn to avoid a shock zone located in a rotating arena (Fig. 1C). This test is more suitable to probe memory functions than the Morris water maze, given that aged mice are poor swimmers. The mice were first habituated to the arena in one 5-min session the day before the first training day. The APA test then consisted of five training days with a single 10-min training session each day.

In this first APA for group assignment, a two-way mixed repeated-measures ANOVA based on the number of shocks that were received revealed a significant effect of day of testing, indicating that learning had occurred ($(F_{4,188}) = 8.96, p < 0.0001$). There was also a significant effect of genotype, with APP23 mice receiving more shocks than their WT littermates ($(F_{1,47}) = 19.47, p < 0.0001$) (Fig. 1D). Similarly, based on the measure of time to the first entry of the shock zone, there was a significant effect of day, with mice showing longer latencies to the first entrance as the number of training days increased ($(F_{4,188}) = 19.79, p < 0.0001$). WT mice exhibited longer latencies to enter the shock zone over the days of testing and there was a significant effect of genotype on time to first entry ($(F_{1,47}) = 13.13, p < 0.0001$) (Fig. 1E). They also performed significantly worse on time to second entry as a measure of short-term memory, ($(F_{1,47}) = 24.16, p < 0.0001$) (Fig. 1F). As the APA performance of the APP23 mice varied significantly, they were therefore assigned to each of the four treatment groups based on matching performance in terms of the number of shocks received on day


5 of the APA in order to reduce differences in performance between treatment groups (Fig. 1G).

Before retesting in the APA, mice were treated once-a-week for 8 weeks with either 1 MHz ultrasound (HighF), 286 kHz frequency ultrasound (LowF) or sham (sham) treatment. For the retest, the shock zone was shifted by 180°, the cues in the room were changed, and the arena was rotated in the opposite direction (Fig. 1H). To perform well in the retest, the mice needed to update their spatial learning in order to learn the new shock zone location, which requires significant cognitive flexibility. A two-way ANOVA with group as a between-subjects factor and day as a repeated measures factor revealed a significant effect of ultrasound treatment group on number of shocks received ($(F_{3,48}) = 11.27, p < 0.0001$) (Fig. 1I). Follow-up multiple comparisons tests showed that HighF mice received significantly fewer shocks than sham mice on days 4 ($p = 0.004$) and 5 ($p = 0.008$). In contrast to HighF treated mice, LowF mice did not show a significant improvement in spatial learning ability compared to sham treated mice. There was no significant effect of ultrasound treatment on time to first entry of the shock zone, which increased over day of training for all groups and revealed a trend towards an effect of both ultrasound treatments ($(F_{3,48}) = 2.36, p = 0.08$) on time to first entry into the shock zone, with a follow-up multiple comparisons test showing that ultrasound treated mice had a longer latency to enter the shock zone on day 5 of the APA task ($p = 0.035$) (Fig. 1J). There was a significant effect of group on the time to the second entry to the shock zone ($(F_{3,48}) = 12.03, p < 0.0001$) and here the HighF group showed a benefit on day 4 of the test (Holm-Sidak multiple comparisons test; $p = 0.01$) (Fig. 1K). The number of shocks received on day 5 of the APA revealed that HighF mice received 43% fewer shocks than sham treated APP23 mice (Holm-Sidak multiple comparisons test; $p = 0.004$) (Fig. 1L). We computed a learning index from the ratio of the number of shocks received on day one and day five of the APA retest, with a lower score indicating better learning. This learning index revealed significantly better learning in HighF treated mice compared to sham treated mice (One-way ANOVA followed by Holm-Sidak multiple comparisons test, $p = 0.027$) (Fig. 1M). Together, these results demonstrate that APP23 mice exhibited an improvement in spatial memory when treated with HighF ultrasound, with LowF ultrasound only resulting in slight improvements.

Improved memory functions occur in the absence of reductions in amyloid plaques and A β levels

We next examined whether the ultrasound treatments might reduce A β levels in brain by first performing Campbell-Switzer silver staining of HighF, LowF and sham treated APP23 mice for plaques (Fig. 2A–C). The analysis revealed no reduction in the total plaque area when the ultrasound treatment groups were compared to the sham treated controls. We calculated the percentage area occupied by plaque for the cortex in 5–10 sections per mouse, assessing plaque burden in a one-in-eight series of sections along the rostral-caudal axis starting from the anterior commissure and ending at the ventral hippocampus. There were no statistically significant differences when comparing sham and ultrasound treatment (one-way ANOVA ($F_{2,36}) = 1.87, p = 0.17$). A t-test to compare HighF to sham revealed a slight increase in plaque burden, but this was not statistically significant ($p = 0.16$) (Fig. 2D). When the number of plaques with an area larger than 20 μm^2 was quantified and normalized to the area of the cortex, no differences in plaque numbers were revealed ($(F_{2,36}) = 0.97, p = 0.39$) (Fig. 2E).

As an additional assessment of amyloid pathology, we sequentially extracted the cortices of the mice to obtain a detergent-soluble fraction (SDC) containing soluble proteins and a detergent-insoluble fraction containing insoluble proteins (guanidine HCl) and measured the levels of the A β species, A β_{40} and



Aβ₄₂, by enzyme-linked immunosorbent assay (ELISA). Our results revealed no significant differences in the levels of Aβ₄₂ in the insoluble fraction (Fig. 2F) (one-way ANOVA, $p = 0.59$) but a significant difference of Aβ₄₂ in the soluble fraction ($p = 0.001$) (Fig. 2G). Levels of Aβ₄₀ were not different between the treatment groups for the insoluble fraction ($p = 0.71$) (Fig. 2H) or the soluble

fraction (Fig. 2I) ($p = 0.51$). We attempted to correlate plaque burden with performance in the APA test for number of shocks on day five of the test (Fig. 2J) and the learning index (Fig. 2K), finding no significant correlations. Together with the analysis of amyloid plaques, these findings reveal that improved memory function in the SUS^{only}-treated APP23 mice occurred in the absence of

Fig. 2 Repeated SUS^{only} treatments at either 1 MHz (HighF) or 286 kHz (LowF) does not reduce plaque burden and amyloid- β levels. **A** Plaque burden and morphology appeared similar when comparing sham treated APP23 mice with **(B)** HighF treated and **(C)** LowF treated APP23 mice. The Campbell-Switzer silver staining method was used which stains both diffuse and compact plaques equally well. Plaque burden and number of large plaques were analyzed by automated thresholding in ImageJ. (Scale bar: 100 μ m). **D** Plaque burden expressed as % area was not significantly different between the three groups (one-way ANOVA $p = 0.16$). **E** There was also no difference in the number of large plaques per mm² of cortex. Cortical tissue was sequentially lysed to generate a detergent-soluble (SDC: sodium deoxycholate) fraction and a detergent-insoluble (GuHCl: guanidine hydrochloride) fraction. **F** Enzyme-linked immunosorbent assays (ELISAs) for A β ₄₀ and A β ₄₂ revealed no difference in detergent-insoluble A β ₄₂ levels, but **(G)** the detergent-soluble A β ₄₂ was higher in the HighF group. **H** Levels of A β ₄₀ were not different between the groups in the detergent-insoluble GuHCl fraction, or **(I)** in the detergent-soluble SDC fraction **(I)**. Violin plots with the median value indicated with a line. **J** There was no correlation between amyloid- β plaque burden and the number of shocks the mice received on day 5 of the APA retest, and **(K)** no correlation between amyloid- β plaque burden and the learning index, calculated as the ratio of the number of shocks received on day one day five of the APA retest (Simple linear regression, slopes did not significantly differ from zero, dashed line is 95% confidence intervals).

amyloid reductions, and that spatial memory as measured in the APA test was not correlated with amyloid- β pathology including plaques.

Ultrasound treatment alters the proteome of APP23 mice in a frequency-dependent manner

Given that ultrasound exerts pleiotropic effects on brain tissue, as reported recently in senescent WT mice [20], we performed label-free quantitative proteomic analysis on cortical lysates of APP23 mice subjected to either HighF, LowF or sham treatment. Principal component analysis (PCA) revealed that the proteomes of ultrasound treated mice grouped together, away from the proteome of sham treated mice, and that the HighF mice showed a relatively larger magnitude of changes in protein expression compared to the LowF animals, mirroring the differences seen in spatial memory functions (Supplementary Fig. 1A).

Out of a total of 2115 proteins identified by our proteomic pipeline, differential analysis revealed 15 upregulated proteins common to both the HighF and LowF mice compared to sham, and no proteins that were downregulated in both treatments when compared to sham (Supplementary Fig. 1B). Heatmap (Fig. 3A) and volcano plot representations of the differentially regulated proteins revealed similar up- or down-regulation effects induced by the HighF versus sham treatment (32 significantly up- and 21 significantly downregulated proteins in volcano plots) (Supplementary Fig. 1B), whereas the LowF effect was, as expected, less impactful, but markedly skewed towards upregulation of protein expression (17 up- and 2 downregulated proteins versus sham) (Supplementary Fig. 1C). The same analysis identified 18 up- and 16 downregulated proteins that were specific to the HighF group compared with the sham treated mice (Fig. 3B), and only 2 up- and 2 downregulated proteins in the LowF group compared with sham treated mice (Fig. 3C).

Our proteomic analysis led to the identification of four expression clusters based on their differentially expressed treatment-effect trajectory (Fig. 3D, E, and Supplementary Fig. 1D, E). Of these clusters, Cluster 1 ($n = 155$ proteins) was characterized by increased expression in the LowF group that was further enhanced by the HighF treatment (Fig. 3D). Cluster 1 was characterized by differential expression specific to Golgi vesicle transport, and establishment of protein localization to the membrane or to the cell periphery. Members of this cluster included SNX1 (member of the sorting nexin family), RAB5A (GTPase involved in endosome transport and found within different cellular components, including axon terminal boutons), and STX1b (involved in exocytosis of synaptic vesicles). Cluster 2 ($n = 147$) was represented by proteins that showed a marked ultrasound frequency-dependent downregulation in their expression (Fig. 3E). The functions associated with this cluster were represented by histone modification and response to hypoxia. Proteins which were downregulated in this cluster are represented by ACTB, SFPQ, NOS1 and MECP2. Interestingly, MECP2 is an intensely studied regulator of synaptic plasticity. Cluster 3

($n = 186$) was composed of proteins with upregulated expression following LowF treatment, but a more moderate increase induced by the HighF treatment (Supplementary Fig. 1D). This cluster was enriched in proteins associated with exocytosis, and axonal genesis and development. Interestingly, proteins belonging to this cluster included MAP1A and MAP6, (microtubule-associated proteins that contribute to axonal development and stabilization). Other members of the cluster were STX1A, SNX4 and CALM3, having functions related to exocytosis. Cluster 4 ($n = 173$) was represented by proteins that showed a steep downregulation starting with the LowF treatment, but a moderate decrease after the HighF treatment (Supplementary Fig. 1E). The cluster was also found to be associated with axonogenesis and axonal development, as well as vesicle organization. Proteins which were dysregulated in this cluster were associated with regulation of the action potential (GPD1L, GNA11, GNAQ) and the localization of vesicles (RAB7A, DCTN2, MAP2).

Together, these findings not only indicate that HighF mice show a relatively larger magnitude of changes to the proteome compared to LowF and sham treated animals, as expected, but they also provide a molecular explanation for the improvements seen in the spatial memory paradigm, through decreased transcriptional silencing of neuronal plasticity-related genes and an upregulation of Golgi-related and synaptic vesicle secretory pathways.

Ultrasound improves brain network connectivity as measured with rsfMRI

AD is associated with a widespread loss of both intra- and inter-network correlations as revealed by resting-state functional MRI (rsfMRI) [28], a feature that has been reproduced in amyloid-depositing transgenic strains [29]. Indeed, upon ultrasound treatment of amyloid-depositing APP23 mice, we generated functional connectivity matrices and found increased rsfMRI connectivity specifically in the hippocampal and salience networks in the HighF group compared to both sham and LowF mice (Fig. 4A–F). These findings indicate that the HighF treatment specifically improves connectivity in memory-related networks compared to the other groups.

Interestingly, stronger negative correlations were observed between the somatosensory network and the striatal and hippocampal networks in the HighF versus LowF (Fig. 4E) and HighF versus sham groups (Fig. 4F). Negative correlations in resting state networks are an underexplored research area yet evidence suggests that these opposing and anti-correlating regions can be interpreted as regions with opposing functions as the brain drifts between internal and external mental states [30]. The enhanced negative correlations in the HighF group may indicate better switching ability across different mental states in these mice.

In contrast to the rsfMRI data, stimulus-evoked fMRI found no differences in ultrasound treated compared to sham treated APP23 mice (data not shown).




Fig. 3 Proteomic analysis of the cortex of APP23 mice subjected to either HighF, LowF or sham treatment reveals treatment-dependent changes. **A** Heatmap of the top significant proteins ($n = 59$) grouped by ultrasound treatment regime. **B** Upset plot revealing the shared and unique number of proteins that were significantly upregulated (left) or downregulated (C) when compared between treatment regimes. **D** Analysis of the proteomic data identifies expression patterns (left), top significant biological processes (middle) and expression networks (right) induced by the HighF and LowF ultrasound treatment. Cluster 1 shows an ultrasound treatment-dependent increase in expression of proteins related to Golgi vesicle transport and dynamics in membrane-associated proteins. **E** Cluster 2 is defined by an ultrasound treatment-dependent decrease in expression. The cluster is characterized by biological processes associated with histone modification.






Fig. 4 HighF ultrasound treated mice show differences in averaged resting-state functional connectivity. Average resting state functional connectivity for selected brain regions for (A) sham treated APP23 mice, (B) LowF treated APP23 mice, and (C) HighF treated APP23 mice. No significant differences in functional connectivity were found when comparing the LowF and sham treated APP23 mice (D); however, HighF treated APP23 mice showed significant differences in functional connectivity when compared to sham treated APP23 mice (E), and LowF treated APP23 mice (F). (Color scaled by Z test statistics; non-black cells were defined as component-component connectivity deemed statistically significant. One sample t-tests, corrected for multiple comparison correction with False Discovery Rate, thresholded at $Q < 0.05$. Red–Yellow cells: positive correlation. Blue–Green cells: negative correlation).

A

Anaesthetic	Isoflurane		Medetomidine		
	T2w	Diffusion	Evoked fMRI	Resting state fMRI	contrast MRI

B**C**

Effect of ultrasound on brain microstructure

We next performed structural MRI and diffusion MRI imaging to investigate changes in brain volume and microstructure (Fig. 5A). Compared to the sham group, both the LowF and HighF groups had decreased local tissue volumes as measured by tensor-based morphometry (TBM). We then fitted the diffusion MRI data to the

neurite-orientation density and dispersion index (NODDI) and found that the HighF treatment group showed a decreased orientation dispersion index (ODI) and a decreased neurite density index (NDI) mainly in the cortex (Fig. 5B). In contrast, the LowF group had increased ODI in the white matter tracts (Fig. 5C). Together, the alterations in the MRI diffusion metrics specifically in

Fig. 5 Changes to brain morphometry and NODDI diffusion measures by group. **A** Time-course of MRI and anesthesia. Diffusion MRI reveals structural changes to the brain following HighF (**B**) and LowF ultrasound treatment (**C**). Red–yellow voxels show significant increases comparing treatment to sham, and blue–green voxels indicate significant reductions when comparing ultrasound treatment to sham. Tensor-based morphometry (TBM) visualized voxels that underwent statistically significant changes indicative of volumetric effects in HighF treated APP23 mice. Neurite orientation dispersion and density imaging (NODDI) revealed changes in neurite density index (NDI), orientation dispersion index (ODI), and isotropic diffusion volume fraction (fISO) obtained from the diffusion model fitting. Similar changes were found in the LowF group. (2 samples t-test results, implemented as randomized test of General Linear Model; statistical maps were corrected for multiple comparisons with Threshold-free Cluster Enhancement (TFCE) at P value < 0.05 (two-tailed). ODI Orientation Dispersion Index, NDI Neurite Density Index, fISO isotropic diffusion volume fraction. Red anatomical orientation indicators: L Left, R Right).

APP23 mice with amyloid plaques may be associated with the observed enhanced cognition determined by the APA spatial memory test given that higher NDI and ODI were correlated with an increased number of shocks and more impaired memory performance in the APA test (Supplementary Fig. 2A, B). The decreased local tissue volume in the treated groups was also associated with increased isotropic diffusion fraction (fISO) predominantly in neocortical areas and the anterior hippocampus, as well as increased volumes of the ventricles (Fig. 5B, C).

We also performed dynamic contrast-enhanced MRI to measure cerebral blood volume (CBV); however, fitting of the Dynamic Susceptibility Contrast (DSC) data resulted in a large fraction of the datasets having CBV maps with predominantly negative values, even after leakage correction, indicating significant levels of BBB leakage in these animals (data not shown). This supports the notion that the BBB is impaired as reported for many neurodegenerative conditions [31]. Although DSC is not optimized for the detection of BBB integrity, we classified the animals into those giving feasible CBV value maps after DSC model fitting as having an intact BBB and those without feasible CBV maps (negative values) as having a leaky BBB. 55% of the sham mice had a leaky BBB by DSC MRI, whereas 78% of the LowF mice and 88% of the HighF mice had a leaky BBB. A Chi-square test showed a statistically non-significant difference in the ratio of animals with a leaky and non-leaky BBB across the treatment groups ($p = 0.8$). This suggests that whereas BBB integrity is impaired in the majority of APP23 mice, its integrity was not impacted by the SUS treatment.

Resting state functional connectivity changes correlates with behavioral improvements in ultrasound-treated APP23 mice. We next asked whether the increased functional connectivity observed in ultrasound treated mice is closely linked to the improvements in memory performance. Therefore, we used a group-independent component analysis to identify a subcortical memory network [22] comprising the posterior hippocampus, thalamus and the retrosplenial-anterior cingulate cortex, and assessed the connectivity strength in this network in correlation with APA performance (Fig. 6A). We found a significant correlation between connectivity of the network and learning ability in the APA test, given that in particular the communication between the anterior thalamus and the retrosplenial cortex was associated with better learning in ultrasound treated APP23 mice (upon grouping HighF and LowF) (Fig. 6B). Connectivity of this memory circuit was significantly correlated with performance in the APA test as determined by the learning index (Fig. 6C). We also measured the strength of the default mode network connectivity but found that this network's connectivity did not correlate with spatial learning performance (data not shown).

We further performed a correlation analysis of the diffusion metrics, NDI and ODI, in the APA test and found that NDI was positively correlated with the number of shocks in the HighF group (Supplementary Fig. 2A). ODI was also positively correlated with the number of shocks (Supplementary Fig. 2B). Together, these data suggest that changes in the brain detected with fMRI or diffusion MRI correlate with spatial learning, possibly indicating

that the detected alterations reflect increased plasticity in response to ultrasound treatment which might lead to improvements in spatial memory functions.

Levels of synaptic tau are reduced in ultrasound treated mice and this correlates with behavioral improvements. We next quantified the level of tau in hippocampal synaptosomes, as we have previously shown that tau mediates A β toxicity in the post-synapse [18]. We found that sham treated APP23 mice had increased levels of tau in the post-synaptic density (PSD) fraction compared to wild-type mice. Interestingly, HighF ultrasound treatment, but not LowF, reduced levels of synaptic tau (One-way ANOVA followed by Holm–Sidak multiple comparisons test $p = 0.04$) (Supplementary Fig. 3A, B). Phosphorylation of synaptic tau at the phospho-epitope pSer 404 was low and not altered by ultrasound (Supplementary Fig. 3C, D). Our protocol successfully enriched for the postsynaptic marker PSD95 (Supplementary Fig. 3E). Levels of synaptic tau correlated with the performance in the APA test, with increased levels of synaptic tau being associated with receiving more shocks (linear regression $R^2 = 0.24$, $p = 0.02$) (Supplementary Fig. 3F, G). In total cortical brain homogenates, levels of tau and phospho-tau (pSer404) were found to be unchanged by the ultrasound treatment, indicating that in APP23 mice ultrasound may affect the redistribution of tau to the synapse (Supplementary Fig. 3H, I).

Comparing (SUS^{only}) HighF-mediated cognitive improvement in APP23 mice with those obtained previously using SUS^{+MB} that achieved BBB opening. We next compared the current data with those obtained in two previously published studies in which we had reported improved spatial memory in the APA paradigm using SUS^{+MB} rather than SUS^{only} [8, 32]. Interestingly, our comparative post hoc analysis suggests that the effect of ultrasound on brain functions can be dissociated from amyloid reductions facilitated by BBB opening (Fig. 6D). Together, this reveals that SUS^{only}, in particular the HighF paradigm, improved memory function, increased neuronal connectivity and altered the proteome in APP23 mice, without lowering A β levels (Fig. 6E).

DISCUSSION

In AD, memory deficits are assumed to be a consequence of the accumulation of A β (and tau) aggregation [33, 34]; however, cognitive deficits can be dissociated from the occurrence of plaques. The loss of synapses in AD may be driven by soluble A β and its initiation of excitotoxic signaling [35]. The toxicity of A β has been shown to be mediated by synaptic tau and driven by intracellular signaling cascades [18] potentially allowing for interventions that spare neurons and synapses from death by antagonizing toxic signaling pathways that would normally be activated in the presence of A β . Previously, we had revealed in APP23 mice with an A β pathology that ultrasound application in combination with the intravenous injection of microbubbles (SUS^{+MB}) both safely and transiently disrupted the BBB; this led to amyloid clearance through increased microglial internalization, as well as memory improvements [8, 32, 36]. The assumption at




Fig. 6 Functional connectivity is increased in HighF and LowF treated mice and correlates with memory performance in the APA test. **A** A subcortical memory network was identified using ICA analysis involving the posterior hippocampus, thalamus and the retrosplenial-anterior cingulate cortex which is involved in spatial learning. **B** In ultrasound treated mice, performance in the APA memory test was positively correlated with the subcortical memory network connectivity, particularly the connectivity between the anterior thalamus and the retrosplenial cortex. (Heat map indicates voxels with $p < 0.05$ correlation). **C** Linear regression of functional connectivity in the subcortical memory circuit (FC t-stat) and the learning index revealed a significant correlation in LowF treated mice ($R^2 = 0.83$, $p = 0.0006$), and a correlation in HighF treated mice ($R^2 = 0.28$, $p = 0.1$). **D** The magnitude of the improvement in learning and memory after ultrasound treatment is equivalent to those obtained in APP23 mice treated with ultrasound plus microbubbles that opens the BBB (SUS^{+MB}) reported in two earlier studies. **E** Graphical representation of the findings of this study: Improved memory, enhanced functional connectivity and an altered proteome were found in APP23 mice in the absence of A β reduction after repeated treatments with scanning ultrasound without microbubbles (SUS^{only}) at 1 MHz (HighF) and, to a lesser extent, at 286 kHz (LowF).

the time was that memory or functional improvements are contingent on reducing A β .

Here, we show that therapeutic ultrasound applied without microbubbles (SUS^{only}), but with parameters shown previously to improve cognition in aged wild-type mice [20], improved memory function, increased neuronal connectivity and induced long-lasting changes in the proteome in APP23 mice, without lowering A β levels. Functional connectivity changes in a subcortical memory network were increased in ultrasound treated mice and were correlated with improved performance in the APA spatial learning paradigm. Changes to the neuronal proteome and brain microstructure were also observed, correlating with ultrasound frequency in the case of proteomics and with memory performance in the case of brain microstructure as measured by diffusion MRI. In contrast, memory performance was not correlated with amyloid pathology. Together, these findings might indicate that the symptomatic impairments seen in APP23 mice (and in human AD) can be targeted without necessitating the removal of amyloid, but through increasing neuronal function and connectivity. A β is a synaptotoxic molecule and the cognitive symptoms of AD are caused by a loss or failure of synapses that mediate memory formation and retention [35]. A β and tau together mediate synaptotoxicity, and this is independent of their aggregation into amyloid plaques or neurofibrillary tangles [18]. HighF ultrasound brain stimulation could be acting on mechanisms responsible for resilience and neural compensation, given that some neurons are spared from degeneration until advanced age and that some individuals are even remarkably resilient to AD [37, 38]. This reduced susceptibility of synapses to the toxic effects of A β might also be partly mediated through a reduction in synaptic tau levels (Supplementary Fig. 3).

The improvements in memory and functional connectivity may be due to changes in synaptic protein expression (in this study detected by proteomics) and alterations in tissue microstructure, blood flow, and free water diffusion resulting from the ultrasound treatment (detected by MRI in this study). It has been shown previously that levels of synaptic proteins can predict the rate of cognitive decline in human AD patients when measured post mortem [39] or with positron emission tomography (PET) [40]. Interestingly, the reduced brain volume detected by T2-weighted MRI in the ultrasound treated mice is consistent with other studies that have shown significantly increased brain volume loss in AD patients in clinical trials [41]. It has been speculated that amyloid plaque removal may explain the volume loss, but this is unlikely the reason given the small volume of brain occupied by plaques compared to the magnitude of changes found on MRI. We found by neurite imaging with MRI that ultrasound treatment changed the microstructure of the brain, reducing NDI and ODI and that this correlated with memory improvement, as a higher NDI and number of shocks were positively correlated (Supplementary Fig. 2). This was somewhat surprising given that NDI and ODI are believed to correlate with the density of axons and dendrites; however, NODDI measures have been shown to for example either increase or decrease following concussion depending on the study which could be due to differences in the study populations [23]. In the context of AD, neurite imaging of the TgCRND8 mouse model of AD showed that NDI and ODI in the hippocampus were higher with increasing amyloid pathology [42]. In cognitively unimpaired older human adults, a greater amyloid burden was associated with higher cortical NDI; however, when tau and amyloid were high, NDI was lower [43], together indicating the complexity of this measure and hinting at the fact that neurite imaging may be able to detect changes in the brain driven by amyloid and tau pathology. How changes to brain microstructure detected in this study relate to changes in cognition could be subject of further studies, but we note that it occurred with both LowF and HighF ultrasound stimulation, although the latter had a greater effect on memory.

The SUS^{only} neuromodulation employed here improves memory in AD mice and in senescent wild-type mice [20]. This finding has some similarities to other brain stimulation methods (such as repetitive transcranial magnetic stimulation) which have been found to improve memory function in healthy humans, specifically by stimulating regions of the prefrontal cortex [44]. There is also evidence that brain stimulation can improve cognitive abilities in patients with AD, and clinical trials are underway [45]. Ultrasound is likely to have both overlapping and distinct mechanisms of action to electrical and magnetic stimulation, as it exerts a mechanical force on brain tissue and mediates its effects through the activation of mechanosensitive ion channels on neurons and glia [46, 47].

To the best of our knowledge, our study for the first time reveals frequency-specific effects of ultrasound on cognition and connectivity in mice. 1 MHz (HighF) was more effective than 286 kHz (LowF) in our study, possibly because of the increased acoustic radiation force exerted at the HighF condition. Another study reported that higher-frequency ultrasound has larger neurostimulatory effects on neurons in the retina [48]. It is assumed that mechanical stimulation of neurons has a role in the effect of ultrasound, given that several different mechanosensitive ion channels are expressed by neurons that can respond to ultrasound [5]. Magnetic resonance acoustic radiation force imaging (MR-ARFI) has shown that because absorption of ultrasound increases with frequency, it results in larger displacements in brain tissue [49, 50]. This increased absorption of high frequency ultrasound may explain the larger bioeffects when APP23 mice were treated at 1 MHz as compared to 286 kHz. However, higher frequencies are more attenuated by the human skull limiting a potential clinical translation. It is plausible that an intermediate ultrasound frequency may have effects equivalent to 1 MHz ultrasound, and this should be explored in future clinical studies.

Along with improved cognitive function, we also detected changes in functional connectivity as measured by MRI. Interestingly, reduced functional connectivity determined by fMRI has been reported for 5xFAD mice [51] and in a rat model of AD [52]. We revealed that in addition to cellular level alterations induced by ultrasound, brain circuits may also be affected as reflected by changes in resting state functional connectivity. Others have shown long-lasting effects (for up to 45 min) in primates after stimulation with 500 kHz ultrasound [53]. FUS^{only} further alters neuronal circuits and behaviors in macaques for up to one hour after stimulation [54]. The long-term changes in functional connectivity we detected in our study two weeks after the last ultrasound treatment may be a consequence of alterations in the neuronal proteome that may underlie the improvements in cognitive function as the most altered cluster of proteins has functions involved in protein localization and targeting and the extension of filopodia (Fig. 3D) as well as axonogenesis (Supplementary Fig. 1D). Stimulating neurons with ultrasound activates calcium signaling acutely [46] and can enhance plasticity and result in long-term potentiation [20] which may be an explanation for the positive changes in resting state functional connectivity that was detected in our study. It remains to be determined whether ultrasound has effects beyond two weeks after the last treatment, although there is compelling evidence from several studies that this type of treatment has long-term effects on brain functions as discussed by us recently [5].

We found that ultrasound stimulation caused changes to the neuronal proteome lasting up to two weeks post-treatment, with the dysregulated clusters being tightly related to synaptic vesicle function, exocytosis, axonogenesis and neuronal signaling. The proteome changes we identified were both frequency dependent and independent, pointing to the mechanisms by which the SUS^{only} treatment could exercise its effects on the AD brain. Indeed, the HighF treatment induced an elevation in Golgi vesicle

transport and membrane dynamics-associated processes and a marked decrease in histone methylation-associated processes. Together with the behavioral and MRI data, our proteomics analysis thus provides mechanistic evidence that could explain the HighF treatment effects: profound changes in chromatin organization and removal of transcriptional silencing through a decrease in the H3K9 methylation, simultaneous with increased secretory activity, and altogether leading to increased network connectivity and improved cognitive functions.

A limitation of our study is, given that APP23 mice are characterized by premature lethality during the first 4–6 months of age which presents a challenge to breeding planning [18], that the experimental groups were comprised of 75% male and 25% female mice; however, the ratio of male to female mice was the same for all treatment groups. Our study could therefore not ascertain a possible difference between male and female mice in their response to ultrasound. A second potential limitation of our study is that the treatment protocol with weekly treatments for two months was designed to be similar to a clinically relevant protocol. We did not assess the effect of ultrasound in real-time during ultrasound neurostimulation as we were primarily interested in the amelioration of clinical symptoms rather than studying the online effects of ultrasound, and the immediate effects of the ultrasound application or additional timepoints remain to be determined.

In an AD context, ultrasound has previously been used to achieve concomitant BBB opening (FUS^{+MB}) in mouse models [8, 55], and in a growing number of clinical trials enrolling small numbers of AD patients [11]. Following preclinical work in mice [8, 32], FUS^{+MB} has also been combined with the anti-A β antibody aducanumab in three AD patients to achieve increased A β clearance [56], but the therapeutic effects of ultrasound might go beyond increased brain uptake of aducanumab [57]. Furthermore, a clinical trial has been conducted in AD patients using ultrasound shockwaves in the absence of microbubbles [14]. As reviewed recently, it is still incompletely understood how to best utilize ultrasound to achieve therapeutic outcomes [5]. The current study reveals in an AD context that SUS^{only} can differentially induce long-term functional improvements in the brain, as shown by quantitative proteomics and functional magnetic resonance imaging. Importantly, these improvements occurred in the absence of A β reductions. Our study therefore implies that cognitive improvement and A β clearance can be dissociated, with important implications for treatment strategies. We conclude that our findings are relevant for the rapidly growing space of therapeutic ultrasound, whether it is used as a neuromodulatory tool or a BBB-opening tool to facilitate drug delivery.

DATA AVAILABILITY

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD050248.

REFERENCES

- Goedert M, Spillantini MG. A century of Alzheimer's disease. *Science*. 2006;314:777–81.
- Jack CR Jr. Advances in Alzheimer's disease research over the past two decades. *Lancet Neurol*. 2022;21:866–9.
- Padmanabhan P, Götz J. Clinical relevance of animal models in aging-related dementia research. *Nat Aging*. 2023;3:481–93.
- Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. *Proc Natl Acad Sci USA*. 1997;94:13287–92.
- Blackmore DG, Razansky D, Götz J. Ultrasound as a versatile tool for short- and long-term improvement and monitoring of brain function. *Neuron*. 2023;111:1174–90.
- Meng Y, Hynynen K, Lipsman N. Applications of focused ultrasound in the brain: from thermoablation to drug delivery. *Nat Rev Neurol*. 2021;17:7–22.

- Jordao JF, Thevenot E, Markham-Coultes K, Scarcelli T, Weng YQ, Xhima K, et al. Amyloid-beta plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. *Exp Neurol*. 2013;248:16–29.
- Leinenga G, Götz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer's disease mouse model. *Sci Transl Med*. 2015;7:278ra33.
- Shen Y, Hua L, Yeh CK, Shen L, Ying M, Zhang Z, et al. Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease. *Theranostics*. 2020;10:11794–819.
- Leinenga G, Koh WK, Götz J. Scanning ultrasound in the absence of blood-brain barrier opening is not sufficient to clear beta-amyloid plaques in the APP23 mouse model of Alzheimer's disease. *Brain Res Bull*. 2019;153:8–14.
- Lipsman N, Meng Y, Bethune AJ, Huang Y, Lam B, Masellis M, et al. Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. *Nat Commun*. 2018;9:2336.
- Meng Y, MacIntosh BJ, Shirzadi Z, Kiss A, Bethune A, Heyn C, et al. Resting state functional connectivity changes after MR-guided focused ultrasound mediated blood-brain barrier opening in patients with Alzheimer's disease. *Neuroimage*. 2019;200:275–80.
- Epelbaum S, Burgos N, Canney M, Matthews D, Houot M, Santin MD, et al. Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. *Alzheimers Res Ther*. 2022;14:40.
- Beisteiner R, Matt E, Fan C, Baladyiak H, Schonfeld M, Philipp Novak T, et al. Transcranial Pulse Stimulation with Ultrasound in Alzheimer's Disease-A New Navigated Focal Brain Therapy. *Adv Sci*. 2020;7:1902583.
- Nisbet RM, van der Jeugd A, Leinenga G, Evans HT, Janowicz PW, Götz J. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. *Brain*. 2017;140:1220–30.
- Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. *Nature*. 2006;443:768–73.
- Zhou J, Seeley WW. Network dysfunction in Alzheimer's disease and frontotemporal dementia: implications for psychiatry. *Biol Psychiatry*. 2014;75:565–73.
- Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell*. 2010;142:387–97.
- Choi JJ, Pernot M, Small SA, Konofagou EE. Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice. *Ultrasound Med Biol*. 2007;33:95–104.
- Blackmore DG, Turpin F, Palliyaguru T, Evans HT, Chicoteau A, Lee W, et al. Low-intensity ultrasound restores long-term potentiation and memory in senescent mice through pleiotropic mechanisms including NMDAR signaling. *Mol Psychiatry*. 2021;26:6975–91.
- Nasrallah FA, Tay HC, Chuang KH. Detection of functional connectivity in the resting mouse brain. *Neuroimage*. 2014;86:417–24.
- To XV, Nasrallah FA. Multi-modal magnetic resonance imaging in a mouse model of concussion. *Sci Data*. 2021;8:207.
- To XV, Nasrallah FA. A roadmap of brain recovery in a mouse model of concussion: insights from neuroimaging. *Acta Neuropathol Commun*. 2021;9:2.
- Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. *AJNR Am J Neuroradiol*. 2006;27:859–67.
- Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. *Neuroimage*. 2014;92:381–97.
- Dickie DA, Mikhael S, Job DE, Wardlaw JM, Laidlaw DH, Bastin ME. Permutation and parametric tests for effect sizes in voxel-based morphometry of gray matter volume in brain structural MRI. *Magn Reson Imaging*. 2015;33:1299–305.
- Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. *Neuroimage*. 2009;44:83–98.
- Brier MR, Thomas JB, Snyder AZ, Benzinger TL, Zhang D, Raichle ME, et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. *J Neurosci*. 2012;32:8890–9.
- Grandjean J, Derungs R, Kulic L, Welt T, Henkelman M, Nitsch RM, et al. Complex interplay between brain function and structure during cerebral amyloidosis in APP transgenic mouse strains revealed by multi-parametric MRI comparison. *Neuroimage*. 2016;134:1–11.
- To XV, Vegh V, Nasrallah FA. Towards data-driven group inferences of resting-state fMRI data in rodents: Comparison of group ICA, GIG-ICA, and IVA-GL. *J Neurosci Methods*. 2022;366:109411.
- Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain Barrier: From Physiology to Disease and Back. *Physiological Rev*. 2019;99:21–78.
- Leinenga G, Koh WK, Götz J. A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease. *Alzheimers Res Ther*. 2021;13:76.

33. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med*. 2016;8:595–608.
34. Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Götz J. Amyloid-beta and tau complexity - towards improved biomarkers and targeted therapies. *Nat Rev Neurol*. 2018;14:22–39.
35. Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. *JAMA Neurol*. 2014;71:505–8.
36. Leinenga G, Bodea LG, Schroder J, Sun G, Zhou Y, Song J, et al. Transcriptional signature in microglia isolated from an Alzheimer's disease mouse model treated with scanning ultrasound. *Bioeng Transl Med*. 2023;8:e10329.
37. Oh H, Razlighi QR, Stern Y. Multiple pathways of reserve simultaneously present in cognitively normal older adults. *Neurology*. 2018;90:e197–e205.
38. Stern Y, Barnes CA, Grady C, Jones RN, Raz N. Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience. *Neurobiol Aging*. 2019;83:124–9.
39. Berezcki E, Francis PT, Howlett D, Pereira JB, Hoglund K, Bogstedt A, et al. Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. *Alzheimers Dement*. 2016;12:1149–58.
40. Mecca AP, Chen MK, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, et al. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. *Alzheimers Dement*. 2020;16:974–82.
41. Barkhof F, Knopman DS. Brain Shrinkage in Anti-beta-Amyloid Alzheimer Trials: Neurodegeneration or Pseudo-atrophy? *Neurology*. 2023;100:941–2.
42. Colon-Perez LM, Ibanez KR, Suarez M, Torroella K, Acuna K, Ofori E, et al. Neurite orientation dispersion and density imaging reveals white matter and hippocampal microstructure changes produced by Interleukin-6 in the TgCRND8 mouse model of amyloidosis. *Neuroimage*. 2019;202:116138.
43. Vogt NM, Hunt JFV, Adluru N, Ma Y, Van Hulle CA, Iii DCD, et al. Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. *Alzheimers Dement*. 2022;18:65–76.
44. Luber B, Lisanby SH. Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS). *Neuroimage*. 2014;85:961–70.
45. Menardi A, Dotti L, Ambrosini E, Vallesi A. Transcranial magnetic stimulation treatment in Alzheimer's disease: a meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization. *J Neurol*. 2022;269:5283–301.
46. Yoo S, Mittelstein DR, Hurt RC, Lacroix J, Shapiro MG. Focused ultrasound excites cortical neurons via mechanosensitive calcium accumulation and ion channel amplification. *Nat Commun*. 2022;13:493.
47. Oh SJ, Lee JM, Kim HB, Lee J, Han S, Bae JY, et al. Ultrasonic Neuromodulation via Astrocytic TRPA1. *Curr Biol*. 2020;30:948.
48. Menz MD, Ye P, Firouzi K, Nikoozadeh A, Pauly KB, Khuri-Yakub P, et al. Radiation Force as a Physical Mechanism for Ultrasonic Neurostimulation of the Ex Vivo Retina. *J Neurosci*. 2019;39:6251–64.
49. Hertzberg Y, Volovick A, Zur Y, Medan Y, Vitek S, Navon G. Ultrasound focusing using magnetic resonance acoustic radiation force imaging: application to ultrasound transcranial therapy. *Med Phys*. 2010;37:2934–42.
50. Phipps MA, Jonathan SV, Yang PF, Chaplin V, Chen LM, Grissom WA, et al. Considerations for ultrasound exposure during transcranial MR acoustic radiation force imaging. *Sci Rep*. 2019;9:16235.
51. Kesler SR, Acton P, Rao V, Ray WJ. Functional and structural connectome properties in the 5XFAD transgenic mouse model of Alzheimer's disease. *Netw Neurosci*. 2018;2:241–58.
52. Munoz-Moreno E, Tudela R, Lopez-Gil X, Soria G. Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease. *Alzheimers Res Ther*. 2018;10:16.
53. Munoz F, Meaney A, Gross A, Liu K, Poulipoulos AN, Liu D, et al. Long term study of motivational and cognitive effects of low-intensity focused ultrasound neuromodulation in the dorsal striatum of nonhuman primates. *Brain Stimul*. 2022;15:360–72.
54. Verhagen L, Gallea C, Folloni D, Constans C, Jensen DE, Ahnine H, et al. Offline impact of transcranial focused ultrasound on cortical activation in primates. *Elife*. 2019;8:e40541.
55. Xhima K, Markham-Coultes K, Kofoed RH, Saragovi HU, Hynynen K, Aubert I. Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies. *Brain*. 2022;145:2806–22.
56. Rezaei AR, D'Haese PF, Finomore V, Carpenter J, Ranjan M, Wilhelmson K, et al. Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease. *N Engl J Med*. 2024;390:55–62.
57. Götz J, Padmanabhan P. Ultrasound and antibodies - a potentially powerful combination for Alzheimer disease therapy. *Nat Rev Neurol*. 2024; online ahead of print.

ACKNOWLEDGEMENTS

We thank members of our team (Drs Rachel de las Heras and Jae Song) as well as Rowan Tweedale for critical reading of our manuscript. The MS data acquired herein were facilitated by access to the Australian Proteome Analysis Facility (APAF) funded under the Australian Government's National Collaborative Research Infrastructure Strategy (NCRIS)/Education Investment Fund.

AUTHOR CONTRIBUTIONS

The study was designed by GL and JG. The experiments were performed by GL, XVT, GR-S and TS. The data were analyzed by GL, XVT, LGB, JY, AC and LD. The paper was written by GL, LGB, FN and JG with input and approval from all authors. Funding was provided by JG.

FUNDING

We acknowledge support from the Estate of Dr. Clem Jones, the State Government of Queensland (DSITI, Department of Science, Information Technology and Innovation), the National Health and Medical Research Council of Australia (GNT1176326, GNT1145580 and GA39196), the Alzheimer's Association (Chicago) grant 22-AAIA-965230, and the Terry and Maureen Hopkins Foundation to JG. LGB is the recipient of a Dementia Australia Foundation Mid-Career Research Fellowship. Open Access funding enabled and organized by CAUL and its Member Institutions.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL

All animal experimentation was approved by the Animal Ethics Committee of the University of Queensland (approval number QBI/554/17).

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41380-024-02509-5>.

Correspondence and requests for materials should be addressed to Jürgen Götz.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024